Huangkui capsule combined with finerenone attenuates diabetic nephropathy by regulating the JAK2/STAT3 signaling pathway based on network pharmacology, molecular docking, and experimental verification
HKC combined with finerenone mitigates DN progression by inhibiting the JAK2/STAT3 pathway and reducing inflammation, apoptosis, and tubular injury. These findings provide a mechanistic basis for clinical application of this combination therapy.
Authors
- James Lu (ORCID: https://orcid.org/0000-0002-9687-5607)
- Jingjing Dai (ORCID: https://orcid.org/0000-0002-7841-7936)
- Xingyu Liu
- Gang Yu Liu (ORCID: https://orcid.org/0000-0002-6946-7552)
- Yang Fu (ORCID: https://orcid.org/0000-0002-8221-3354)
- Chunjiang Zhang (ORCID: https://orcid.org/0000-0002-2297-5023)
- Xiaoping Yang (ORCID: https://orcid.org/0000-0002-8298-1273)
Institutions
- First Affiliated Hospital of Shihezi University Medical College (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-04
- DOI
- https://doi.org/10.3389/fphar.2025.1625286
- Citations
- 3
- Primary Topic
- Pharmacological Effects of Natural Compounds
- Type
- article
- Field-Weighted Citation Impact
- 4.67
Funders
- Shihezi University
- Xinjiang Production and Construction Corps